Skip to content
March 28, 2024

Equity.Guru

Investment information for the new generation

Search

Lexaria

Special Delivery $19.043M Market Capitalization Lexaria Bioscience Corp. (LEXX.Q) is a biotechnology company developing DehydraTECH™, the Company’s proprietary drug delivery technology. In addition to enhancing the speed and efficiency of…
Eye Don’t Believe It   Fill Disclosure: weekly roundups are intended to provide a quick introduction to various companies. They are not intended to be deep dives or opinion…
Closing the Diabetic Loop Before we get into this week’s sector roundup, let’s talk about diabetes. I am a sucker for sweets, so much so that I was diagnosed…
Smart Watch, Healthy Heart   There was an opportunity for a pun in the headline and I took it. In this week’s sector roundup, we are going to be…
Digital Medicine Society   The world is on fire, inflation is through the roof, and there is a literal war occurring in Ukraine. While I believe it is important…
Old Memories I have always been a sucker for nostalgia. When I first started writing for Equity Guru, I spent most of my time covering biotechnology companies. Whether they…
Lexaria Bioscience (LEXX.Q) announced today that its DehydraTECH™ technology has been embraced by consumer brands and is now available for sale in over 7,000 stores across the US. “Lexaria’s…
Lexaria Bioscience (LEXX.Q) announced today that dosing has been completed for its HYPER-H21-2 study, the Company’s second human clinical study of 2021.   Hypertension, also known as high blood…
Lexaria Bioscience (LEXX.Q) announced today that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results.     The VIRAL-A20-3 study was performed using Sprague-Dawley rats, with…
Lexaria Bioscience (LEXX.Q) today announced results from its antiviral drug molecular characterization study VIRAL-MC21-1 recently completed by Canada’s premier federally funded research organization, the National Research Council (NRC).  …